A new Extraordinary General Meeting ("EGM") will be convened by the Board of Directors with an agenda proposed by
The current Board of Directors of
An invitation to this new EGM to elect both members of the Nomination Committee and a new Board of Directors will be sent out at the start of next week.
Hans Peter Bøhn, as the only remaining member of the Nomination Committee, may be contacted to propose new members of the Nomination Committee and new members of the Board of Directors.
The Board and the company continue to further preserve cash resources and as a result, Malene Brondberg, current interim Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO") will transition out of the Company. A search for a new CEO is expected to commence immediately after a new Board of Directors of
Chairman,
Contacts
Malene Brondberg, Interim CEO and CFO of
+ 44 7561 431 762
ir@nordicnanovector.com
International Media:
+44 203 928 6900
nordicnanovector@medistrava.com
Media in
+47 916 10 911
sjf@lillebyfrisch.no
About
- Betalutin® and Humalutin®, both CD37-targeting radioimmunotherapies incorporating the beta emitter lutetium-177 to treat non-Hodgkin's lymphoma (NHL);
- Alpha37, a CD37-targeting radioimmunotherapy candidate incorporating the alpha-emitting radionuclide lead-212, currently being explored with partner Oranomed for chronic lymphocytic leukaemia;
- Multiple fully humanized anti-CD37 antibodies with potential in haematological cancers and autoimmune diseases; and
-
A CD37
DOTA CAR-T cell opportunity in haematological cancers, which is being advanced via a research collaboration with theUniversity of Pennsylvania .
Further information can be found at www.nordicnanovector.com.
https://news.cision.com/nordic-nanovector/r/nordic-nanovector-update-following-shareholder-vote-against-proposed-merger-with-apim-therapeutics,c3681134
(c) 2022 Cision. All rights reserved., source